Paper No. ______
`
`Filed on behalf of Apotex Inc.
`By: Kenneth J. Burchfiel
`
`Grant S. Shackelford
`
`Sughrue Mion, PLLC
`
`2100 Pennsylvania Ave., NW
`
`Washington, DC 20037
`
`Telephone: 202-293-7060
`
`Facsimile: 202-293-7860
`
`email:
`kburchfiel@sughrue.com
`gshackelford@sughrue.com
`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`APOTEX INC.
`Petitioner
`
`v.
`
`MERCK & CO., INC.
`Patent Owner
`__________________
`
`Patent No. 5,691,336
`__________________
`
`
`
`APOTEX INC.’S EXHIBIT LIST
`
`(Inter Partes Review of U.S. Patent No. 5,691,336)
`
`
`
`Filed on behalf of Apotex Inc.
`By: Kenneth J. Burchfiel
`
`Grant S. Shackelford
`
`Sughrue Mion, PLLC
`
`2100 Pennsylvania Ave., NW
`
`Washington, DC 20037
`
`Telephone: 202-293-7060
`
`Facsimile: 202-293-7860
`
`email:
`kburchfiel@sughrue.com
`gshackelford@sughrue.com
`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`APOTEX INC.
`Petitioner
`
`v.
`
`MERCK & CO., INC.
`Patent Owner
`__________________
`
`Patent No. 5,691,336
`__________________
`
`
`
`APOTEX INC.’S EXHIBIT LIST
`
`(Inter Partes Review of U.S. Patent No. 5,691,336)
`
`
`
`
`
`Apotex
`Exhibit
`#
`
`APOTEX INC. Exhibit List for
`Inter Partes Review of U.S. Patent No. 5,691,336
`
`Description
`
`Ex. 1001 U.S. Patent No. 5,691,336 to Dorn et al.
`
`Ex. 1002 Declaration of Longqin Hu, Ph. D. ("Hu Decl.")
`
`Ex. 1003 U.S. Patent No. 5,637,699 to Dorn et al.
`
`Ex. 1004 U.S. Patent No. 5,070,082 to Murdock et al.
`
`Ex. 1005 Murdock, K.C., et al., N-Phosphoryl Derivatives of Bisantrene.
`Antitumor Prodrugs with Enhanced Solubility and Reduced Potential
`for Toxicity, J. MED. CHEM., 36, 2098-2101 (July 23, 1993)
`
`Ex. 1006 U.S. Patent No. 3,661,926 to Van Den Bos et al.
`
`Ex. 1007 Atanassova, T. et al., Synthesis of N-substituted 2-imidazolidinone,”
`PHARMAZIE, 42(9), 670-671 (1991)
`
`Ex. 1008 Bundgaard, H. et al., Prodrugs as drug delivery systems IV: N-mannich
`bases as potential novel prodrugs for amides, ureides, amines, and
`other NH-acidic compounds, J. PHARM. SCI., 69, 44-46 (1980)
`
`Ex. 1009 Bundgaard, H. (ed.), Design of Prodrugs, Chapter 1: “Design of
`prodrugs: Bioreversible derivatives for various functional groups and
`chemical entities,” Preface and 1-92 (1985)
`
`Ex. 1010 Bundgaard, H. (ed.), Design of Prodrugs, Chapter 7: “Prodrugs for
`improved formulation properties,” 243-269 (1985)
`
`Ex. 1011 Bundgaard, H., Formation of Prodrugs of Amines, Amides, Ureides,
`and Imides, METHODS IN ENZYMOLOGY, 112, 347-359 (1985)
`
`Ex. 1012 Balant, L.P. et al., Prodrugs for the improvement of drug absorption via
`different routes of administration, EUR. J. DRUG METABOL.
`PHARMACOKIN., 15(2), 143-153 (1990)
`
`Ex. 1013 Avis, K.E. et al. (eds.), Pharmaceutical Dosage Forms: Parenteral
`Medications Volume 1, Chapter 2: Duma, R.J. et al. Parenteral Drug
`1
`
`
`
`
`
`
`
`Apotex
`Exhibit
`#
`
`APOTEX INC. Exhibit List for
`Inter Partes Review of U.S. Patent No. 5,691,336
`
`Description
`
`Administration: Routes, Precautions, Problems, Complications and
`Drug Delivery Systems,” 17-58 (1992)
`
`Ex. 1014 Varia, S.A. et al., Phenytoin Prodrugs III: Water-Soluble Prodrugs for
`Oral and/or Parenteral Use, J. PHARM. SC. 73(8) 1068-1073 (1984)
`
`Ex. 1015 Fischer, J.H., et al., Fosphenytoin Clinical Pharmacokinetics and
`Comparative Advantages in the Acute Treatment of Seizures, CLIN.
`PHARMACOKINET., 42(1), 33-58 (2003)
`
`Ex. 1016 Kearney, et al., The in Vitro Enzymic Labilities of Chemically Distinct
`Phosphomonoester Prodrugs, PHARM. RES., 9(4), 497-503 (1992)
`
`Ex. 1017 Sommer, F.G., et al., Pain Accompanying Leg Venography: A
`Comparison of Sodium and Methylglucamine Diatrizoates, RADIOLOGY,
`133, 790-791 (1979)
`
`Ex. 1018 Chromy, V., et al., D(-)-N-Methylglucamine Buffer for pH 8.5 to 10.5,
`CLIN. CHEM., 24(2), 379-381 (1978)
`
`Ex. 1019 U.S. Patent No. 3,981,994 to Hoffmann et al.
`
`Ex. 1020 U.S. Patent No. 3,867,397 to Bohner et al.
`
`Ex. 1021 Berge, S.M. et al., Pharmaceutical Salts, J. PHARM. SCI., 66(1), 1-19
`(1977)
`
`Ex. 1022 U.S. Patent No. 4,748,174 to Veronesi
`
`Ex. 1023 Merck & Co. Emend® (aprepitant) Drug Information Label
`
`Ex. 1024 Merck & Co. Emend® (fosaprepitant dimeglumine) Drug Information
`Label
`
`Ex. 1025 U.S. Patent Application Serial No. 08/169,889, filed December 17,
`1993, abandoned
`
`
`
`2
`
`
`
`
`
`Apotex
`Exhibit
`#
`
`APOTEX INC. Exhibit List for
`Inter Partes Review of U.S. Patent No. 5,691,336
`
`Description
`
`Ex. 1026 Ex parte Dong, Appeal No. 2011-010047 (P.T.A.B. Jan. 28, 2013)
`
`Ex. 1027 Ex parte Cao, Appeal No. 2010-004081 (B.P.A.I. Sept. 19, 2011)
`
`Ex. 1028 Hale, J.J. et al., Structural Optimization Affording 2-(R)-(l-(R)-3,5-
`Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-
`l,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-
`Acting Morpholine Acetal Human NK-1 Receptor Antagonist, J. MED.
`CHEM., 41, 4607-4614 (1998)
`
`Ex. 1029 Hale, J.J., et. al., Phosphorylated Morpholine Acetal Human
`Neurokinin-1 Receptor Antagonists as Water-Soluble Prodrugs, J. MED.
`CHEM., 43, 1234-1241 (2000)
`
`
`
`3
`
`
`
`
`
`
`
`APOTEX INC. Exhibit List for
`Inter Partes Review of U.S. Patent No. 5,691,336
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Grant Shackelford/
`Grant S. Shackelford
`Reg. No. 70,504
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave, NW
`Washington, DC 20037
`Telephone: (202) 293-7060
`Facsimile: (202) 293-7860
`
`4
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. §§ 42.6(e) and 42.105(a))
`
`The undersigned hereby certifies that the above-captioned APOTEX INC.’S
`
`EXHIBIT LIST and Exhibits 1026-1029 were served on July 24, 2015 by filing
`
`these documents through the Patent Review Processing System as well as
`
`delivering copies via electronic mail upon the following attorneys of record for the
`
`Patent Owner:
`
`Bruce M. Wexler (brucewexler@paulhastings.com)
`Preston K. Ratliff, II (prestonratliff@paulhastings.com)
`Gregory A. Morris (gregorymorris@paulhastings.com)
`Naveen Modi (naveenmodi@paulhastings.com)
`Richard C. Billups (richard_billups@merck.com)
`Gerard M. Devlin, Jr. (gerard_devlin@merck.com)
`
`
`
`DATE: July 24, 2015
`
`
`/Grant Shackelford/
`Grant S. Shackelford
`Reg. No. 70,504
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave, NW
`Washington, DC 20037
`Telephone: (202) 293-7060
`Facsimile: (202) 293-7860
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
